|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 267.19 USD | +0.49% |
|
-1.63% | -2.92% |
| 03-12 | Quest Diagnostics Incorporated Appoints Timothy Wentworth as Director | CI |
| 03-12 | Cigna Shares Rise After Bernstein Upgrade | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.29 | 3.55 | 3.79 | 3.93 | 4.09 | |||||
Return on Total Capital | 6.16 | 6.71 | 7.29 | 8.05 | 8.75 | |||||
Return On Equity % | 11.1 | 14.64 | 11.79 | 8.63 | 15.13 | |||||
Return on Common Equity | 11.01 | 14.5 | 11.36 | 7.87 | 14.4 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 13.19 | 13 | 12.89 | 10.51 | 9.3 | |||||
SG&A Margin | 7.36 | 7.27 | 7.36 | 5.9 | 4.93 | |||||
EBITDA Margin % | 5.72 | 5.73 | 5.53 | 4.63 | 4.38 | |||||
EBITA Margin % | 5.57 | 5.59 | 5.4 | 4.53 | 4.3 | |||||
EBIT Margin % | 4.69 | 4.7 | 4.6 | 3.92 | 3.73 | |||||
Income From Continuing Operations Margin % | 3.11 | 3.74 | 2.75 | 1.53 | 2.29 | |||||
Net Income Margin % | 3.08 | 3.69 | 2.64 | 1.39 | 2.17 | |||||
Net Avail. For Common Margin % | 3.08 | 3.69 | 2.64 | 1.39 | 2.17 | |||||
Normalized Net Income Margin | 2.5 | 2.49 | 2.32 | 1.95 | 1.89 | |||||
Levered Free Cash Flow Margin | 0.55 | 5.86 | 4.56 | 1.52 | 3.55 | |||||
Unlevered Free Cash Flow Margin | 0.95 | 6.26 | 5 | 1.9 | 3.87 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.12 | 1.21 | 1.32 | 1.6 | 1.75 | |||||
Fixed Assets Turnover | 102.16 | 121.76 | 153.27 | 289.88 | 322.46 | |||||
Receivables Turnover (Average Receivables) | 12.97 | 11.36 | 11.19 | 11.86 | 10.41 | |||||
Inventory Turnover (Average Inventory) | 43.88 | 36.95 | 32.64 | 35.85 | 35.54 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.83 | 0.73 | 0.77 | 0.84 | 0.85 | |||||
Quick Ratio | 0.49 | 0.59 | 0.55 | 0.56 | 0.67 | |||||
Operating Cash Flow to Current Liabilities | 0.17 | 0.21 | 0.24 | 0.18 | 0.17 | |||||
Days Sales Outstanding (Average Receivables) | 28.15 | 32.14 | 32.62 | 30.86 | 35.05 | |||||
Days Outstanding Inventory (Average Inventory) | 8.32 | 9.88 | 11.18 | 10.21 | 10.27 | |||||
Average Days Payable Outstanding | 49.08 | 54.03 | 56.81 | 54.46 | 57.49 | |||||
Cash Conversion Cycle (Average Days) | -12.61 | -12.02 | -13 | -13.39 | -12.17 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 72.62 | 70.19 | 67.69 | 77.52 | 75.14 | |||||
Total Debt / Total Capital | 42.07 | 41.24 | 40.37 | 43.67 | 42.9 | |||||
LT Debt/Equity | 66.89 | 63.28 | 61.48 | 70.16 | 73.72 | |||||
Long-Term Debt / Total Capital | 38.75 | 37.18 | 36.66 | 39.52 | 42.09 | |||||
Total Liabilities / Total Assets | 69.54 | 68.77 | 69.66 | 73.54 | 73.48 | |||||
EBIT / Interest Expense | 7.29 | 7.29 | 6.42 | 6.46 | 7.33 | |||||
EBITDA / Interest Expense | 9.08 | 9.03 | 7.82 | 7.63 | 8.6 | |||||
(EBITDA - Capex) / Interest Expense | 8.05 | 7.91 | 6.7 | 6.69 | 7.74 | |||||
Total Debt / EBITDA | 3.37 | 3.01 | 2.86 | 2.79 | 2.61 | |||||
Net Debt / EBITDA | 2.78 | 2.35 | 2.07 | 2.08 | 1.89 | |||||
Total Debt / (EBITDA - Capex) | 3.8 | 3.43 | 3.34 | 3.18 | 2.9 | |||||
Net Debt / (EBITDA - Capex) | 3.14 | 2.69 | 2.41 | 2.37 | 2.1 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 8.53 | 3.7 | 8.17 | 26.56 | 11.24 | |||||
Gross Profit, 1 Yr. Growth % | -5.14 | 2.23 | 7.14 | 3.13 | -1.56 | |||||
EBITDA, 1 Yr. Growth % | -3.96 | 3.8 | 4.14 | 5.53 | 5.25 | |||||
EBITA, 1 Yr. Growth % | -3.84 | 3.92 | 4.15 | 5.78 | 5.45 | |||||
EBIT, 1 Yr. Growth % | -4.78 | 3.95 | 5.57 | 7.28 | 5.85 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -36.21 | 24.58 | -20.79 | -29.67 | 66.44 | |||||
Net Income, 1 Yr. Growth % | -36.57 | 24.29 | -22.97 | -33.5 | 73.47 | |||||
Normalized Net Income, 1 Yr. Growth % | -2.66 | 3.35 | 0.4 | 6.22 | 7.98 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -31.49 | 35.41 | -18.78 | -30.3 | 83 | |||||
Accounts Receivable, 1 Yr. Growth % | 21.8 | 16.11 | 4.43 | 37.91 | 18.55 | |||||
Inventory, 1 Yr. Growth % | 17.6 | 28.34 | 18.17 | 18.55 | 9.65 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -4.59 | -21.82 | -4.15 | -5.59 | 5.92 | |||||
Total Assets, 1 Yr. Growth % | -0.36 | -7.07 | 6.17 | 2.04 | 1.31 | |||||
Tangible Book Value, 1 Yr. Growth % | 8.57 | 1.88 | -12.84 | 12.18 | -2.91 | |||||
Common Equity, 1 Yr. Growth % | -6.38 | -4.75 | 3.46 | -11.23 | 1.66 | |||||
Cash From Operations, 1 Yr. Growth % | -30.52 | 20.37 | 36.47 | -12.27 | -7.35 | |||||
Capital Expenditures, 1 Yr. Growth % | 5.48 | 12.22 | 21.47 | -10.62 | -13.8 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -92.34 | 1K | -15.99 | -58.49 | 160.6 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -87.61 | 580.97 | -13.65 | -52.69 | 127.14 | |||||
Dividend Per Share, 1 Yr. Growth % | 9.9K | 12 | 9.82 | 13.82 | 7.86 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 6.47 | 6.09 | 5.91 | 17 | 18.65 | |||||
Gross Profit, 2 Yr. CAGR % | -4.31 | -1.52 | 4.74 | 5.11 | 0.76 | |||||
EBITDA, 2 Yr. CAGR % | -7.28 | -0.16 | 4.12 | 4.73 | 5.39 | |||||
EBITA, 2 Yr. CAGR % | -7.32 | -0.04 | 4.19 | 4.86 | 5.61 | |||||
EBIT, 2 Yr. CAGR % | -3.81 | -0.51 | 4.94 | 6.29 | 6.56 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 2.84 | -10.86 | -0.44 | -25.36 | 8.19 | |||||
Net Income, 2 Yr. CAGR % | 2.52 | -11.21 | -1.94 | -28.43 | 7.4 | |||||
Normalized Net Income, 2 Yr. CAGR % | -1.56 | 0.3 | 2.08 | 3.27 | 7.1 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 8.18 | -3.68 | 5.08 | -24.76 | 12.94 | |||||
Accounts Receivable, 2 Yr. CAGR % | 18.65 | 18.92 | 10.12 | 19.08 | 27.86 | |||||
Inventory, 2 Yr. CAGR % | 18.27 | 22.85 | 23.15 | 18.36 | 14.01 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -2.54 | -13.63 | -13.43 | -20.22 | 0 | |||||
Total Assets, 2 Yr. CAGR % | -0.28 | -3.78 | -0.69 | 4.09 | 1.67 | |||||
Tangible Book Value, 2 Yr. CAGR % | -4.89 | 5.62 | -5.51 | -1.24 | 4.36 | |||||
Common Equity, 2 Yr. CAGR % | 1.94 | -5.57 | -0.95 | -4.16 | -5 | |||||
Cash From Operations, 2 Yr. CAGR % | -12.93 | -8.55 | 28.17 | 9.42 | -9.85 | |||||
Capital Expenditures, 2 Yr. CAGR % | 4.84 | 8.8 | 16.75 | 4.2 | -12.22 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -44.9 | -8.16 | 203.83 | -40.38 | 4.01 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -36.9 | -8.14 | 142.4 | -35.76 | 3.66 | |||||
Dividend Per Share, 2 Yr. CAGR % | 900 | 958.3 | 10.91 | 11.8 | 10.8 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 52.95 | 5.54 | 6.78 | 12.39 | 15.05 | |||||
Gross Profit, 3 Yr. CAGR % | 12.04 | -2.18 | 1.32 | 4.2 | 2.84 | |||||
EBITDA, 3 Yr. CAGR % | 24.02 | -3.73 | 1.37 | 4.73 | 4.9 | |||||
EBITA, 3 Yr. CAGR % | 24.13 | -3.72 | 1.46 | 4.87 | 5.05 | |||||
EBIT, 3 Yr. CAGR % | 18.8 | -1.29 | 1.62 | 5.89 | 6.14 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 26.96 | 9.63 | -14.15 | -11.33 | -2.49 | |||||
Net Income, 3 Yr. CAGR % | 26.71 | 9.32 | -15.17 | -13.85 | -3.86 | |||||
Normalized Net Income, 3 Yr. CAGR % | 14.39 | 0.05 | 0.5 | 3.44 | 4.82 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 14.28 | 16.59 | -8.85 | -8.36 | 1.18 | |||||
Accounts Receivable, 3 Yr. CAGR % | 12.75 | 17.8 | 13.88 | 18.09 | 18.91 | |||||
Inventory, 3 Yr. CAGR % | 9.68 | 21.54 | 21.27 | 21.6 | 15.38 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 9.05 | -9.44 | -10.58 | -20.76 | -12.32 | |||||
Total Assets, 3 Yr. CAGR % | 0.36 | -2.6 | -0.58 | 0.21 | 3.15 | |||||
Tangible Book Value, 3 Yr. CAGR % | -8.28 | -2.4 | -0.75 | -0.03 | -1.8 | |||||
Common Equity, 3 Yr. CAGR % | 4.72 | -0.34 | -2.79 | -4.5 | -2.26 | |||||
Cash From Operations, 3 Yr. CAGR % | 24.02 | -3 | 4.51 | 12.95 | 3.51 | |||||
Capital Expenditures, 3 Yr. CAGR % | 29.77 | 7.24 | 12.87 | 6.81 | -2.18 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -55.78 | 49.54 | -10.8 | 57.26 | -2.51 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -47.13 | 39.44 | -9.97 | 41.24 | -2.14 | |||||
Dividend Per Share, 3 Yr. CAGR % | 364.16 | 382.03 | 397.32 | 11.87 | 10.47 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 34.3 | 33.98 | 32.04 | 9.98 | 11.38 | |||||
Gross Profit, 5 Yr. CAGR % | 12 | 10.75 | 9.05 | 0.7 | 1.09 | |||||
EBITDA, 5 Yr. CAGR % | 22.98 | 18.75 | 15.65 | -0.24 | 3.05 | |||||
EBITA, 5 Yr. CAGR % | 23.48 | 19.02 | 15.74 | -0.18 | 3.19 | |||||
EBIT, 5 Yr. CAGR % | 20.19 | 15.49 | 13.07 | 1.92 | 3.68 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 24.06 | 24.76 | 15.22 | -5.9 | -5.83 | |||||
Net Income, 5 Yr. CAGR % | 23.51 | 24.41 | 14.39 | -7.62 | -6.77 | |||||
Normalized Net Income, 5 Yr. CAGR % | 18.22 | 12.71 | 9.32 | 1.43 | 3.09 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 16.95 | 19.42 | 10.53 | -2.05 | -0.69 | |||||
Accounts Receivable, 5 Yr. CAGR % | 37.03 | 42.34 | 11.69 | 18.31 | 18.91 | |||||
Inventory, 5 Yr. CAGR % | - | 83.76 | 14.88 | 20.25 | 18.32 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 16.75 | 11.47 | -0.57 | -13.92 | -12.85 | |||||
Total Assets, 5 Yr. CAGR % | 21.14 | 18.44 | -0.06 | 0.01 | 0.32 | |||||
Tangible Book Value, 5 Yr. CAGR % | 40.06 | 41.5 | -7.02 | -1.83 | 1.22 | |||||
Common Equity, 5 Yr. CAGR % | 27.98 | 26.76 | 2.41 | -1.98 | -3.68 | |||||
Cash From Operations, 5 Yr. CAGR % | 12.3 | 16.2 | 25.66 | 1.79 | -1.49 | |||||
Capital Expenditures, 5 Yr. CAGR % | 20.14 | 22.42 | 24.4 | 6.01 | 2.07 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -31.38 | -0.56 | -4.34 | 3.46 | -4.86 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -23.86 | 0.56 | -2.74 | 2.37 | -4.49 | |||||
Dividend Per Share, 5 Yr. CAGR % | 151.19 | 156.95 | 161.81 | 168.67 | 172.77 |
- Stock Market
- Equities
- CI Stock
- Financials Cigna
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















